Acorda Therapeutics Inc. (NASDAQ:ACOR) is a stock that investors should take a bite out of.

After closing at $0.31 in the most recent trading day, Acorda Therapeutics Inc. (NASDAQ: ACOR) closed at 0.33, up 6.45%. In other words, the price has increased by $+0.0200 from its previous closing price. On the day, 1048714 shares were traded. ACOR reached its highest trading level at $0.3300 during the session, while it also had its lowest trading level at $0.2766.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.

Sponsored

Ratios:

Our goal is to gain a better understanding of ACOR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.50 and its Current Ratio is at 1.90. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 2.10.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on June 17, 2021, Upgraded its rating to Buy and sets its target price to $10 from $5 previously.

On August 14, 2019, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $31 to $6.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 17 when COHEN RON sold 2,289 shares for $1.70 per share. The transaction valued at 3,895 led to the insider holds 129,601 shares of the business.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 0.08 while its Price-to-Book (P/B) ratio in mrq is 0.06.

Stock Price History:

Over the past 52 weeks, ACOR has reached a high of $4.99, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of the stock is 0.4274, while the 200-Day Moving Average is calculated to be 1.2350.

Shares Statistics:

The stock has traded on average 309.63K shares per day over the past 3-months and 265.73k shares per day over the last 10 days, according to various share statistics. A total of 24.28M shares are outstanding, with a floating share count of 24.10M. Insiders hold about 0.60% of the company’s shares, while institutions hold 27.50% stake in the company. Shares short for ACOR as of Jul 14, 2022 were 322.61k with a Short Ratio of 0.76, compared to 216.86k on Jun 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 1.33% and a Short% of Float of 1.34%.

Earnings Estimates

Its stock is currently analyzed by 0 different market analysts. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was $-2.5. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.

Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.

Revenue Estimates

1 analysts predict $36.97M in revenue for the current quarter. It ranges from a high estimate of $31.01M to a low estimate of $31.01M. As of the current estimate, Acorda Therapeutics Inc.’s year-ago sales were $38.16M, an estimated decrease of -3.10% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $26M, a decrease of -9.90% less than the figure of $-3.10% in the same quarter last year. There is a high estimate of $26M for the next quarter, whereas the lowest estimate is $26M.

A total of 1 analysts have provided revenue estimates for ACOR’s current fiscal year. The highest revenue estimate was $120.38M, while the lowest revenue estimate was $120.38M, resulting in an average revenue estimate of $129.07M. In the same quarter a year ago, actual revenue was $152.97M, down -15.60% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $120.51M in the next fiscal year. The high estimate is $120.51M and the low estimate is $120.51M. The average revenue growth estimate for next year is down -6.60% from the average revenue estimate for this year.